Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference on September 30, 2024. The company will be involved in two key events:
1. A fireside chat from 2:30 PM to 3:00 PM ET, featuring CEO and Founder Brian Thomas, CMO Dr. Sarah Noonberg, and SVP Preclinical Alan Brooks.
2. A panel discussion titled "Genome editing for gene insertion and gene correction - where we are and what's next" from 5:00 PM to 5:30 PM ET, with CEO Brian C. Thomas participating.
A live webcast of the fireside chat will be available on the company's investor relations website, with replays of both events accessible for a time.
Metagenomi (Nasdaq: MGX), un'azienda di medicinali genetici di precisione, ha annunciato la sua partecipazione alla 8ª Conferenza annuale sui medicinali genetici di Chardan il 30 settembre 2024. L'azienda sarà coinvolta in due eventi chiave:
1. Un fireside chat dalle 14:30 alle 15:00 ET, con il CEO e Fondatore Brian Thomas, il CMO Dr. Sarah Noonberg e il SVP Preclinico Alan Brooks.
2. Una discussione di panel intitolata "Modifica del genoma per l'inserzione e la correzione genica - dove siamo e cosa ci aspetta" dalle 17:00 alle 17:30 ET, con la partecipazione del CEO Brian C. Thomas.
Una diretta streaming del fireside chat sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda, con repliche di entrambi gli eventi accessibili per un periodo di tempo.
Metagenomi (Nasdaq: MGX), una empresa de medicamentos genéticos de precisión, ha anunciado su participación en la 8ª Conferencia Anual de Medicamentos Genéticos de Chardan el 30 de septiembre de 2024. La empresa estará involucrada en dos eventos clave:
1. Un fireside chat de 2:30 PM a 3:00 PM ET, con la participación del CEO y fundador Brian Thomas, la CMO Dra. Sarah Noonberg y el SVP Preclínico Alan Brooks.
2. Una discusión de panel titulada "Edición del genoma para la inserción y corrección de genes - dónde estamos y qué sigue" de 5:00 PM a 5:30 PM ET, con la participación del CEO Brian C. Thomas.
Una transmisión en vivo del fireside chat estará disponible en el sitio web de relaciones con inversionistas de la empresa, con repeticiones de ambos eventos accesibles por un tiempo limitado.
Metagenomi (Nasdaq: MGX), ein Unternehmen für präzise genetische Medikamente, hat seine Teilnahme an der 8. Jahreskonferenz für genetische Medikamente von Chardan am 30. September 2024 angekündigt. Das Unternehmen wird an zwei wichtigen Veranstaltungen teilnehmen:
1. Ein Fireside Chat von 14:30 bis 15:00 Uhr ET, mit CEO und Gründer Brian Thomas, CMO Dr. Sarah Noonberg und SVP Preclinical Alan Brooks.
2. Eine Podiumsdiskussion mit dem Titel "Genom-Editierung zur Gen-Einfügung und Gen-Korrektur - wo wir stehen und was als Nächstes kommt" von 17:00 bis 17:30 Uhr ET, bei der CEO Brian C. Thomas teilnimmt.
Ein Live-Übertragung des Fireside Chats wird auf der Investor Relations-Website des Unternehmens verfügbar sein, und Wiederholungen beider Veranstaltungen sind für eine gewisse Zeit zugänglich.
Metagenomi (Nasdaq: MGX), une entreprise de médicaments génétiques de précision, a annoncé sa participation à la 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan le 30 septembre 2024. L’entreprise sera impliquée dans deux événements clés :
1. Un fireside chat de 14h30 à 15h00 ET, avec le PDG et fondateur Brian Thomas, la CMO Dr. Sarah Noonberg et le SVP préclinique Alan Brooks.
2. Une table ronde intitulée "Édition du génome pour l'insertion et la correction de gènes - où nous en sommes et quelle est la suite" de 17h00 à 17h30 ET, avec la participation du PDG Brian C. Thomas.
Un webcast en direct du fireside chat sera disponible sur le site des relations investisseurs de l'entreprise, avec des rediffusions des deux événements accessibles pendant un certain temps.
- None.
- None.
EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that company management will participate in the following events at Chardan's 8th Annual Genetic Medicines Conference:
- Fireside chat on Monday, September 30, 2024, 2:30 PM - 3:00 PM ET with Brian Thomas, CEO and Founder, Dr. Sarah Noonberg, CMO, and Alan Brooks, SVP Preclinical.
- Panel discussion titled, “Genome editing for gene insertion and gene correction - where we are and what's next,” on Monday, September 30, 2024, 5:00 PM - 5:30 PM ET with Brian C. Thomas, CEO and Founder.
A live conference webcast of the fireside chat will be available in the investor section of the company's website at https://ir.metagenomi.co/. Replays for both events will be available for a limited time at the same address.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, including our development candidate, MGX-001, statements concerning the timing of data presentations and publications, and any other statements that are not historical facts. Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contact:
Simon Harnest - CIO, SVP Investor Relations
simon@metagenomi.co
Media Contact:
Ashlye Hodge - Communications Manager
ashlye@metagenomi.co
FAQ
When is Metagenomi (MGX) presenting at Chardan's Genetic Medicines Conference?
Who will represent Metagenomi (MGX) at the Chardan conference fireside chat?
What is the topic of the panel discussion Metagenomi (MGX) is participating in?
How can investors access Metagenomi's (MGX) presentation at the Chardan conference?
